Jennison Associates’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Jennison Associates’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-42,133	Closed	-$15.2M	–	731
2018 Q3	$15.2M	Buy	42,133 +250	+0.6%	+$85.5K	0.01%	431
2018 Q2	$15.3M	Buy	41,883 +20,212	+93%	+$7.2M	0.01%	435
2018 Q1	$6.4M	Buy	21,671 +1,528	+8%	+$451K	0.01%	481
2017 Q4	$8.43M	Buy	+20,143	New	+$7.2M	0.01%	473

Other funds holding EIGR

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates's EIGR Position: Q4 2018 in Review

Jennison Associates sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2018, closing a stake of 42,133 shares — an estimated $15.2M sold.

Jennison Associates first reported a position in EIGR in Q4 2017 and held it in 4 quarters. The position peaked at $15.3M in Q2 2018. 68 funds tracked by Wall St. Rank hold EIGR as of Q4 2018.

Jennison Associates reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Jennison Associates sold 42,133 Eiger BioPharmaceuticals, Inc. shares in Q4 2018, an estimated $15.2M.
Jennison Associates first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2017 and held it in 4 quarters.
Jennison Associates's Eiger BioPharmaceuticals, Inc. position peaked at $15.3M in Q2 2018.
68 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2018.

Based on Jennison Associates's 13F filing for Q4 2018, filed 6 Feb 2019.